Cytodyn Inc (CYDY) NPV

- Add to watchlist
- This stock can be held in a



Business summary
CytoDyn Inc. is a biotechnology company that is focused on developing treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The Company also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The Company is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).
Contact details
Important dates
General stock information
- Short code:
- CYDY
- ISIN:
- US23283M1018
- Market cap:
- $226.27 million
- Shares in issue:
- 718.32 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.